Literature DB >> 12581773

Successful treatment of enterovirus-induced myocarditis with interferon-alpha.

Luciano Daliento1, Fiorella Calabrese, Francesco Tona, Alida L P Caforio, Giandomenico Tarsia, Annalisa Angelini, Gaetano Thiene.   

Abstract

No randomized, placebo-controlled studies have investigated interferon-alpha therapy in enterovirus-proven myocarditis. This report describes 2 patients with enterovirus-induced myocarditis (1 with associated Churg-Strauss syndrome) who at follow-up endomyocardial biopsy showed clinical and hemodynamic improvement and viral clearance (using polymerase chain reaction) after interferon-alpha therapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12581773     DOI： 10.1016/s1053-2498(02)00565-x

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN： 1053-2498            Impact factor:   10.247


  10 in total

Review 1.  Diagnostic use of the endomyocardial biopsy: a consensus statement.

Authors:  Gaetano Thiene; Patrick Bruneval; John Veinot; Ornella Leone
Journal:  Virchows Arch       Date:  2013-06-08       Impact factor: 4.064

2.  Spontaneous activation of a MAVS-dependent antiviral signaling pathway determines high basal interferon-β expression in cardiac myocytes.

Authors:  Efraín E Rivera-Serrano; Nicole DeAngelis; Barbara Sherry
Journal:  J Mol Cell Cardiol       Date:  2017-08-16       Impact factor: 5.000

3.  A single-amino-acid polymorphism in reovirus protein μ2 determines repression of interferon signaling and modulates myocarditis.

Authors:  Susan C Irvin; Jennifer Zurney; Laura S Ooms; James D Chappell; Terence S Dermody; Barbara Sherry
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

4.  Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specific in the cardiac protective response.

Authors:  Michael J Stewart; Kathleen Smoak; Mary Ann Blum; Barbara Sherry
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 5.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

6.  IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection.

Authors:  Lianna Li; Barbara Sherry
Journal:  Virology       Date:  2009-11-06       Impact factor: 3.616

7.  Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses.

Authors:  Jennifer Zurney; Kristina E Howard; Barbara Sherry
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

8.  High Frequency of Detection by PCR of Viral Nucleic Acid in The Blood of Infants Presenting with Clinical Myocarditis.

Authors:  Kathleen E Simpson; Gregory A Storch; Caroline K Lee; Kent E Ward; Saar Danon; Catherine M Simon; Jeffrey W Delaney; Alan Tong; Charles E Canter
Journal:  Pediatr Cardiol       Date:  2015-10-26       Impact factor: 1.655

9.  Remission of CVB3-induced myocarditis with Astragaloside IV treatment requires A20 (TNFAIP3) up-regulation.

Authors:  Jun Gui; Ruizhen Chen; Wei Xu; Sidong Xiong
Journal:  J Cell Mol Med       Date:  2015-03-01       Impact factor: 5.310

10.  Cardiac fibroblasts aggravate viral myocarditis: cell specific coxsackievirus B3 replication.

Authors:  Diana Lindner; Jia Li; Konstantinos Savvatis; Karin Klingel; Stefan Blankenberg; Carsten Tschöpe; Dirk Westermann
Journal:  Mediators Inflamm       Date:  2014-10-13       Impact factor: 4.711
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.